文献速递免疫规划妇幼与学校卫生

中国9-14岁女孩单剂Cecolin与Gardasil头对头免疫原性比较:一项随机开放标签临床试验

Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial.
PubMed 文献 · Vaccine · 2025-03-21

该随机开放标签临床试验于2023年2月23日开始(NCT06345885),198名中国9-14岁女孩接种单剂Cecolin或Gardasil,评估接种后1个月和2个月HPV16/18血清阳转率和几何平均滴度(GMT)。结果显示Cecolin组HPV16/18的GMT显著高于Gardasil组,血清阳转率和GMT比非劣效于Gardasil,两组不良事件发生率相似,无统计学显著差异。结论认为单剂Cecolin在中国9-14岁女孩中的免疫原性和安全性与Gardasil相当,支持使用单剂Cecolin提高HPV疫苗接种覆盖率以预防宫颈癌。

要点

  • 接种后1个月,Cecolin组和Gardasil组HPV16血清阳转率均达100%。
  • Cecolin组HPV16和HPV18的GMT显著高于Gardasil组,GMT比分别为1.5(1.1,2.1)和2.84(2.0,4.1)。
  • 单剂Cecolin的血清阳转率和GMT比非劣效于Gardasil,结果在2个月时保持一致。

核心结论

  • 单剂Cecolin在中国9-14岁女孩中的免疫原性和安全性与Gardasil相当,支持使用单剂Cecolin提高HPV疫苗接种覆盖率以预防宫颈癌。

研究设计与样本

  • 随机开放标签临床试验,于2023年2月23日开始(NCT06345885),198名中国9-14岁女孩接种单剂Cecolin或Gardasil。

主要发现

  • 接种后1个月,Cecolin组和Gardasil组HPV16血清阳转率均达100%。
  • 接种后1个月,HPV18血清阳转率Cecolin组为97.9%(95%CI:92.5%,99.7%),Gardasil组为95.6%(95%CI:89.1%,98.8%)。
  • Cecolin组HPV16的GMT显著高于Gardasil组,GMT比为1.5(1.1,2.1);HPV18的GMT比為2.84(2.0,4.1)。
  • 单剂Cecolin的血清阳转率和GMT比非劣效于Gardasil,结果在2个月时保持一致。
  • 两组不良事件发生率相似,无统计学显著差异。

关键数值与推荐

  • 非劣效性判定标准为95%置信区间下限超过-5%。

临床怎么用

  • 原文结论支持使用单剂Cecolin以提高HPV疫苗接种覆盖率以预防宫颈癌。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The World Health Organization (WHO) urges global administration of at least one dose of the HPV vaccine, particularly for girls aged 9-14, to work towards the elimination of cervical cancer. However, data on the efficacy of a single dose of Cecolin®, a bivalent HPV vaccine, remain quite limited. Therefore, it is crucial to design studies investigating the protective effects of a single dose of Cecolin® in Chinese girls. METHODS: The randomized clinical trial began on February 23, 2023 (NCT06345885). 198 Chinese girls aged 9-14 received a single dose of Cecolin® or Gardasil®. Seroconversion rates and geometric mean titers (GMTs) for HPV16 and HPV18 were assessed at one and two months post-vaccination. Non-inferiority was declared if the lower limit of the 95 % confidence interval (CI) exceeded -5 %. Safety of vaccine was evaluated in all vaccinated participants. RESULTS: At one month post-vaccination, both the Cecolin® and Gardasil® groups achieved 100 % seroconversion for HPV16 antibodies. The seroconversion rates for HPV18 were 97.9 % (95 % CI: 92.5 %, 99.7 %) in the Cecolin® group and 95.6 % (95 % CI: 89.1 %, 98.8 %) in the Gardasil® group. The GMTs in the Cecolin® group were significantly higher than those in the Gardasil® group for both HPV types, with GMT ratios of 1.5 (1.1, 2.1) for HPV16 and 2.84 (2.0, 4.1) for HPV18. The seroconversion rates and GMT ratios one month after a single dose of Cecolin® were non-inferior to those of Gardasil®, with results remaining consistent at two months. The incidence of adverse events was similar between the two groups throughout the study, with no statistically significant differences. CONCLUSION: The immunogenicity and safety of a single dose of Cecolin® in Chinese girls aged 9-14 years were comparable to those of Gardasil. These findings support the use of single-dose Cecolin® to enhance HPV vaccination coverage for cervical cancer prevention.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Xie F, Du K, Li J, et al. Head-to-head immunogenicity comparison of one-dose Cecolin and Gardasil in Chinese girls aged 9-14 years: A randomized and open-label clinical trial. Vaccine. 2025. PMID: 40120437. doi:10.1016/j.vaccine.2025.127015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。